Johnson & Amp;Johnson reported this Friday that about two thousand 100 million dollars were offered for his Lifescan Inc. unit, which manufactures products to monitor blood glucose, by the private investment firm Platinum Equity.
J & AMP; J had said in January last year that he was evaluating options for his diabetes care companies, specifically Lifescan, Animas Corp. and Calibra Medical Inc., whose sales have been falling since 2012.
"(...) After an extensive review of all strategic options, we trust that the company will have a promising future with Platinum Equity," Ashley Mcevoy, president of the group of medical devices for J&AP consumers, said in a statement.
The company said that the period of acceptance of the offer would end on June 15, unless it was extended, and during that time there will be consultations with the pertinent company committees.
Lifescan had net income of approximately 1,500 million dollars in 2017, said J & AMP; J.